Iambic Therapeutics has attached pricing terms to the IPO it previewed last month, outlining a deal that it said should bring in about $135 million in net proceeds to support its clinical pipeline and AI drug-discovery platform. According to a Securities and Exchange Commission filing, the San Diego biotech plans to offer 9.4 million shares at $15 to $17 each.
At the midpoint of that range, Iambic expects roughly $150 million in gross proceeds, with net proceeds of approximately $135 million after expenses. That figure could rise to $155.9 million if underwriters fully exercise an option to buy an additional 1.4 million shares at the same price.
Use Of Proceeds
The largest allocation in the filing is $75 million for IAM1363, an oral, brain-penetrant, small-molecule HER2 inhibitor now in a phase 1 study in patients with advanced HER2-altered solid tumors. Iambic said it also wants to use that funding to launch phase 2 and phase 3 studies for the program.
Another $15 million is earmarked for IAM217, a brain-penetrant allosteric inhibitor of KIF18A being developed for ovarian cancer, triple-negative breast cancer and other solid tumors. A further $15 million is designated for a phase 1 study of IAM-C1, a selective dual inhibitor of CDK2 and CDK4 aimed at breast cancer and CCNE1-amplified cancers.
Iambic also plans to spend $20 million on its “molecular superintelligence platform,” including training new versions of its Enchant and NeuralPLexer AI models. That matters because the filing frames the software not as a stand-alone story but as infrastructure supporting internal drug programs, a positioning that may read better in public markets than a pure platform pitch.
Balance Sheet And Strategy
The IPO would add to an already strong cash position. Iambic had $207.9 million on hand at the end of June and said that, if the offering proceeds as planned, it expects to fund operations through the end of 2028.
That runway helps explain the strategic message in the filing. Iambic is not coming public as a company trying to prove it can generate candidates; it is asking investors to finance expensive clinical execution after years of private backing. The biotech raised a $53 million series A in 2021, a $100 million series B in 2023 and another roughly $100 million round in November 2025.
Partners have also validated interest in its technology. Revolution Medicines, Jazz Pharmaceuticals, Lundbeck, Nvidia and Bayer have all signed deals with Iambic, while AbbVie joined last month. In February, Takeda signed a multiyear agreement worth up to $1.7 billion in biobucks to access Iambic’s drug discovery platforms, including NeuralPLexer, initially across oncology, gastrointestinal and inflammation indications.
The broader signal is that 2026’s IPO window remains open for biotechs that can present both platform differentiation and near-term clinical catalysts. For Iambic, the test shifts from attracting partners and private capital to showing that AI-enabled discovery can hold investor support once the cost and risk move into human studies.
